OP0275-PARE THE UNACCEPTABLE DELAY TO DIAGNOSIS IN AXIAL SPONDYLOARTHRITIS; DEVELOPING A CALL TO ACTION FOR A GLOBAL HEALTHCARE CHALLENGE

Background: The current delay to diagnosis from symptom onset represents one of the greatest challenges in axial spondyloarthritis (axSpA). Research shows an average global almost 7 years 1 – and as long 15 some cases 2 during which time condition can progress considerably lead irreversible damage. Data indicates that women wait longer than men for a 3 , there has been very limited reducing axSpA diagnosis. hugely detrimental impact on individual’s quality life. Because disease frequently early individuals are left with untreated or incorrectly-treated symptoms at formative period their life course, whilst they await Objectives: Axial Spondyloarthritis International Federation (ASIF) set out coordinate comprehensive evidence-based review factors influencing produce definitive report shines light these barriers, well providing resource ultimately empower range international stakeholders reduce this delay. Methods: A full literature was carried identify relevant available evidence exploring In autumn 2020 ASIF held two virtual forum events, involving patients patient group representatives, researchers, rheumatologists other healthcare professionals, methodically explore key across different systems opportunities addressing these. Break-out discussions were participants asked personal societal effects diagnostic delay; reasons it occurs; initiatives tackle challenge. Alongside stakeholder testimonies, best practices around world also identified. 92 participated events; represented professionals 23 countries five continents. Results: findings activities incorporated within new ‘Delay Diagnosis’ report, first definitively sets lived realities perspective identified important commonalities contributing 7-year delay, including: •Poor awareness axSpA, particularly primary care services •Complexities diagnosing •Poorly defined referral pathways •Insufficient access appropriate diagnostics highlights significant wider society, foundation future advocacy work. series recommendations have identified, implementation will help instigate tangible Conclusion: Despite longstanding challenges, now clear transforming how is diagnosed world. This message needs be heard acted upon urgently by all those involved management delivery care. programme work ASIF’s Delay Diagnosis project respond centred supporting associations globally take call action forward throughout 2021 beyond. References: [1]Zhao et al; Diagnostic spondyloarthritis: systematic meta-analysis; Rheumatology [2]Garrido-Cumbrera, M., Poddubnyy, D., Gossec, L. al. European Map Spondyloarthritis: Capturing Patient Perspective—an Analysis 2846 Patients Across 13 Countries. Curr Rheumatol Rep 21, 19 (2019) [3]Jovani Understanding How Differs Between Women Men: Systematic Review Metaanalysis; Journal December 2016 Disclosure Interests: Wendy Gerhart Employee of: I employed Janssen Canada 1992 - 2017, Mehmet Tuncay Duruöz: None declared, Jo Lowe Grant/research support from: No financial grants received individually. However, my role Project Manager currently funded partially UCB Global Novartis Global, Dale Webb Speakers bureau: Novartis, Individually, no. But NASS receives AbbVie, Biogen, Eli Lilly, Janssen, UCB, Lillann Wermskog Spafo Norge small amount funding ongoing projects Novartis., Davies Boehringer Ingelheim, Novartis; covers staff salaries projects, content outputs not influenced funders., Richard Howard Shareholder Amgen, Bristol-Myers Squibb, GSK, Johnson & Johnson, Merck, Pfizer, Teva. own <20 shares any stock stocks represent <4% investments, Consultant Yes, but then donated Spondylitis Association America, personally grants. SAA BI, J&J, UCB., Michael Mallinson No. But, disclosure: honoraria past, participating advisory board activities, Abbvie, Pfizer Cheryl L Koehn OUR ORGANIZATION, ARTHRITIS CONSUMER EXPERTS, HAS. HAVE NOT AS AN INDIVIDUAL. HERE IS PUBLICLY AVAILABLE DISCLOSURE ON ALL ONLINE AND PRINT MATERIALS, PRESENTATIONS, MEETINGS, GOVERNMENT CONSULTATIONS: https://jointhealth.org/about-principles.cfm?locale=en-CA Over past 12 months, ACE grants-in-aid Arthritis Canada, Amgen Canadian Institutes Health Research, Association, Lilly Hoffman-La Roche Ltd., Knowledge Translation Merck Sandoz Sanofi St. Paul’s Hospital (Vancouver), University British Columbia.